Aptar Pharma, a division of AptarGroup, has unveiled plans for a significant capacity expansion at its Congers site in New York, US.  

The extension is aimed at addressing increasing demand for proprietary drug delivery systems in North America.  

The expansion includes the addition of moulds and assembly lines in clean room manufacturing settings for its Unidose Nasal Spray Systems. 

The extension is set to come online in Q4 2024.

In response to the growing demand for nasal saline solutions, the company is also installing an assembly line to expand the manufacturing of its bag-on-vale technology.  

In addition, Aptar Pharma plans to extend clean room space at the facility for its Child-Resistant Senior-Friendly closure solutions. 

The added capacity will add an additional 28,500ft² building extension to bolster warehousing, clean room and manufacturing capabilities at the site. 

Aptar Pharma president Gael Touya said: “Our Aptar Pharma business in North America has shown robust growth in recent years, with increasing customer demand across all product lines.  

“This expansion is a key step in the next phase of our global expansion programme, designed to continue to meet the growing needs of our customers in the region, which will ultimately benefit patients.” 

The Congers site has been operational since 2002, initially focusing on the production of VP3 pumps, but now manufactures a diverse range of drug delivery products for nasal and injectable routes.  

Aptar Pharma’s expansion in North America is part of the company’s broader expansion plan, which includes developments in France, China and India, reinforcing its 'local for local' strategy.